Gasparello Jessica, Papi Chiara, Zurlo Matteo, Volpi Stefano, Gambari Roberto, Corradini Roberto, Casnati Alessandro, Sansone Francesco, Finotti Alessia
Section of Biochemistry and Molecular Biology, Department of Life Sciences and Biotechnology, University of Ferrara, 44121 Ferrara, Italy.
Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, 43124 Parma, Italy.
Pharmaceutics. 2023 Aug 10;15(8):2121. doi: 10.3390/pharmaceutics15082121.
One of the most appealing approaches for regulating gene expression, named the "microRNA therapeutic" method, is based on the regulation of the activity of microRNAs (miRNAs), the intracellular levels of which are dysregulated in many diseases, including cancer. This can be achieved by miRNA inhibition with antimiRNA molecules in the case of overexpressed microRNAs, or by using miRNA-mimics to restore downregulated microRNAs that are associated with the target disease. The development of new efficient, low-toxic, and targeted vectors of such molecules represents a key topic in the field of the pharmacological modulation of microRNAs. We compared the delivery efficiency of a small library of cationic calix[4]arene vectors complexed with fluorescent antimiRNA molecules (Peptide Nucleic Acids, PNAs), pre-miRNA (microRNA precursors), and mature microRNAs, in glioma- and colon-cancer cellular models. The transfection was assayed by cytofluorimetry, cell imaging assays, and RT-qPCR. The calix[4]arene-based vectors were shown to be powerful tools to facilitate the uptake of both neutral (PNAs) and negatively charged (pre-miRNAs and mature microRNAs) molecules showing low toxicity in transfected cells and ability to compete with commercially available vectors in terms of delivery efficiency. These results could be of great interest to validate microRNA therapeutics approaches for future application in personalized treatment and precision medicine.
一种最具吸引力的基因表达调控方法,即“微小RNA疗法”,是基于对微小RNA(miRNA)活性的调控,在包括癌症在内的许多疾病中,其细胞内水平会失调。对于过表达的微小RNA,可通过使用抗微小RNA分子抑制微小RNA来实现调控;对于与目标疾病相关的下调微小RNA,则可通过使用微小RNA模拟物来恢复其表达。开发新型高效、低毒且靶向的此类分子载体是微小RNA药理调控领域的一个关键课题。我们在胶质瘤和结肠癌细胞模型中比较了与荧光抗微小RNA分子(肽核酸,PNA)、前体微小RNA(微小RNA前体)和成熟微小RNA复合的阳离子杯[4]芳烃载体小文库的递送效率。通过细胞荧光测定法、细胞成像分析和逆转录定量聚合酶链反应(RT-qPCR)对转染进行了检测。结果表明,基于杯[4]芳烃的载体是促进中性分子(PNA)和带负电荷分子(前体微小RNA和成熟微小RNA)摄取的有力工具,在转染细胞中显示出低毒性,并且在递送效率方面能够与市售载体相竞争。这些结果对于验证微小RNA治疗方法在未来个性化治疗和精准医学中的应用可能具有重要意义。